Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 5/20 | 0.53 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.45 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.45 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2761963 | 0.82 | NAMPT (0.68) | MEN1KMT2AMAPTALDH1A1NAMPT | |
| SCHEMBL6285345 | 0.81 | F2 (0.47) | MEN1KMT2AMAPTALOX15LMNA | |
| SCHEMBL6281210 | 0.80 | LMNA (0.49) | MEN1KMT2AMAPTNAMPTALOX15 | |
| SCHEMBL2762150 | 0.80 | NAMPT (0.62) | MEN1KMT2AMAPTALDH1A1NAMPT | |
| SCHEMBL6283335 | 0.78 | NAMPT (0.64) | MEN1KMT2AMAPTALDH1A1NAMPT | |
| SCHEMBL2762003 | 0.77 | MAPT (0.68) | MEN1KMT2AMAPTALDH1A1NAMPT | |
| SCHEMBL2761957 | 0.76 | MAPT (0.51) | MEN1KMT2AMAPTALDH1A1NAMPT | |
| SCHEMBL13196624 | 0.74 | CA2 (0.74) | MEN1KMT2AMAPTALDH1A1ALOX15 | |
| SCHEMBL6284564 | 0.74 | MAPT (0.72) | MEN1KMT2AMAPTALDH1A1NAMPT | |
| SCHEMBL2762125 | 0.74 | CA2 (0.60) | MEN1KMT2AMAPTALDH1A1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343963-B2 | Sulfamoyl-phenyl-ureido compounds and their use as medicament | 4SC AG (DE) | 2013-01-01 | — | — | US | disclosed |
| EP-2391601-A1 | SULFAMOYL- PHENYL-UREIDO BENZAMIDINE-DERIVATIVES AS ANTIMALARIAL AGENTS | 4SC AG (DE) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086177-A1 | SULFAMOYL- PHENYL-UREIDO BENZAMIDINE-DERIVATIVES AS ANTIMALARIAL AGENTS | 4SC AG (DE) | 2010-08-05 | — | — | WO | disclosed |
| US-20100197640-A1 | NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT | 4SC AG (DE) | 2010-08-05 | — | — | US | disclosed |
| US-6949567-B2 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2005-09-27 | — | — | US | disclosed |
| EP-1395548-A1 | DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS | 4SC AG (DE) | 2004-03-10 | — | — | EP | disclosed |
| US-20030119876-A1 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2003-06-26 | — | — | US | disclosed |
| US-20020165236-A1 | Compounds for the treatment of protozoal diseases | 4SC AG (DE) | 2002-11-07 | — | — | US | disclosed |
| WO-2002070467-A1 | DERIVATIVES OF DIPHENYLUREA, DIPHENYLOXALIC ACID DIAMIDE AND DIPHENYLSULFURIC ACID DIAMIDE AND THEIR USE AS MEDICAMENTS | 4SC AG (DE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165236-A1 | Compounds for the treatment of protozoal diseases | PKD2, PPOX, PKD1 | MEN1 2642/4885KMT2A 2215/4885MAPT 2767/4885 |
| US-20030119876-A1 | Compounds for the treatment of protozoal diseases | CLIC1, PKD2, PKD1 | MEN1 1654/4885KMT2A 3794/4885MAPT 2803/4885 |
| US-20100197640-A1 | NOVEL SULFAMOYL-PHENYL-UREIDO COMPOUNDS AND THEIR USE AS MEDICAMENT | SLC14A1, UTS2R, UROD | MEN1 2878/4885KMT2A 2192/4885MAPT 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.